Trial Profile
A Multicenter, Double-blind, Randomized Controlled, add-on Phase 2/3 Study of the Safety and Efficacy of Meplazumab in Patients With COVID-19
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Meplazumab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Pacific Meinuoke Biopharmaceutical
- 14 Sep 2023 Status changed from recruiting to completed.
- 03 Mar 2022 Status changed from not yet recruiting to recruiting.
- 22 Feb 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.